Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.

Detailed Description:

Vitiligo is a pigmentary disorder characterized by depigmented and hypopigmented macules and patches. There are forms of vitiligo which are more resistant to treatment, including segmental vitiligo and acral vitiligo. Previous studies have shown that a low energy helium-neon (633 nm) laser can cause increased proliferation of melanocytes and repigmentation in segmental-type vitiligo. The goal of this study is to verify these results and show efficacy in other recalcitrant forms of vitiligo including acral vitiligo and post melanocyte-keratinocyte transplantation vitiligo.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Be at least 18 years old

Have active or stable segmental vitiligo on the neck or face, acral vitiligo, or have undergone recent melanocyte-keratinocyte transplantation procedure (MKTP)

Agree to abide by the Investigator's guidelines regarding photosensitizing drugs and photoprotection

Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form

Agree to follow and undergo all study-related procedures

Exclusion Criteria:

Women who are lactating, pregnant, or planning to become pregnant

Patients with a recent history of melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation

Patients with a known history of photosensitivity disorders

Photosensitizing medications may be continued throughout of the study at the discretion of the investigator

Patients with a known history of melanoma or non-melanoma skin cancers

Concomitant use of tanning beds

Any reason the investigator feels the patient should not participate in the study

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01259986